<DOC>
	<DOCNO>NCT00826033</DOCNO>
	<brief_summary>L- [ 3-18F ] -α-methyltyrosine ( 18F-FMT ) amino-acid tracer positron emission tomography ( PET ) . The investigator evaluate value 18F-FMT PET assessment therapy response patient lung cancer compare 2- [ 18F ] -fluoro-2-deoxy-D-glucose ( 18F-FDG ) PET . The patient lung cancer underwent PET study 18F-FDG 18F-FMT radio-/chemotherapy . The investigator use ratio SUVmax mediastinal ( N2 ) lymph node SUVmax primary tumor ( N/P ratio ) . All patient divide two group N/P ratio &lt; 1 N/P ratio≥1 , survival time estimate Kaplan-Meier method .</brief_summary>
	<brief_title>Fluorine-18-α-Methyltyrosine Positron Emission Tomography ( 18F-FMT PET ) Therapy Response Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Fluorides</mesh_term>
	<criteria>primary lung cancer All patient receive firstline chemotherapy Patients diabetus mellitus</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Fluorine-18-α-methyltyrosine</keyword>
	<keyword>Positron emission tomography</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>monitoring</keyword>
</DOC>